Is Pharma (LON:ISPH) , the Chester based specialty pharmaceuticals company, has announced the UK launch of its xerostomia (dry mouth) treatment, Aquoral. Xerostomia is a common side effect of chemo and radiotherapy for cancer that can cause extreme discomfort. Aquoral is a spray that coats the mucous membranes of the mouth and relieves this pain and is classed as a medical device. Aquoral is already marketed in the UK and France. ISPH shares have depreciated by 19% over the last year.  IS Pharma Plc is currently graded b by LCF research.

Unlock the rest of this article with a 14 day trial

Unlock with Email
Unlock with Google

Already have an account?
Login here